Literature DB >> 23702928

Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Nai-Kong V Cheung1, Michael A Dyer.   

Abstract

Neuroblastoma is a solid tumour that arises from the developing sympathetic nervous system. Over the past decade, our understanding of this disease has advanced tremendously. The future challenge is to apply the knowledge gained to developing risk-based therapies and, ultimately, improving outcome. In this Review we discuss the key discoveries in the developmental biology, molecular genetics and immunology of neuroblastoma, as well as new translational tools for bringing these promising scientific advances into the clinic.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23702928      PMCID: PMC4386662          DOI: 10.1038/nrc3526

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  199 in total

1.  Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors.

Authors:  S Modak; K Kramer; S H Gultekin; H F Guo; N K Cheung
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  Chromosome 1p and 11q deletions and outcome in neuroblastoma.

Authors:  Edward F Attiyeh; Wendy B London; Yael P Mossé; Qun Wang; Cynthia Winter; Deepa Khazi; Patrick W McGrady; Robert C Seeger; A Thomas Look; Hiroyuki Shimada; Garrett M Brodeur; Susan L Cohn; Katherine K Matthay; John M Maris
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

Review 3.  Targeting natural killer cells and natural killer T cells in cancer.

Authors:  Eric Vivier; Sophie Ugolini; Didier Blaise; Christian Chabannon; Laurent Brossay
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 4.  Interleukin-15 biology and its therapeutic implications in cancer.

Authors:  Jason C Steel; Thomas A Waldmann; John C Morris
Journal:  Trends Pharmacol Sci       Date:  2011-10-25       Impact factor: 14.819

5.  Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion.

Authors:  Ruth Ladenstein; Ulrike Pötschger; Dimitris Siabalis; Alberto Garaventa; Christophe Bergeron; Ian J Lewis; Jerry Stein; Janice Kohler; Peter J Shaw; Wolfgang Holter; Vito Pistoia; Jean Michon
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

Review 6.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

7.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Authors:  Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

8.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

9.  Autonomic neurocristopathy-associated mutations in PHOX2B dysregulate Sox10 expression.

Authors:  Mayumi Nagashimada; Hiroshi Ohta; Chong Li; Kazuki Nakao; Toshihiro Uesaka; Jean-François Brunet; Jeanne Amiel; Delphine Trochet; Teruhiko Wakayama; Hideki Enomoto
Journal:  J Clin Invest       Date:  2012-08-27       Impact factor: 14.808

10.  Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

Authors:  Nai-Kong V Cheung; Irene Y Cheung; Brian H Kushner; Irina Ostrovnaya; Elizabeth Chamberlain; Kim Kramer; Shakeel Modak
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

View more
  316 in total

1.  Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Authors:  Fjoralba Zeka; Anneleen Decock; Alan Van Goethem; Katrien Vanderheyden; Fleur Demuynck; Tim Lammens; Hetty H Helsmoortel; Joëlle Vermeulen; Rosa Noguera; Ana P Berbegall; Valérie Combaret; Gudrun Schleiermacher; Geneviève Laureys; Alexander Schramm; Johannes H Schulte; Sven Rahmann; Julie Bienertová-Vašků; Pavel Mazánek; Marta Jeison; Shifra Ash; Michael D Hogarty; Mirthala Moreno-Smith; Eveline Barbieri; Jason Shohet; Frank Berthold; Tom Van Maerken; Frank Speleman; Matthias Fischer; Katleen De Preter; Pieter Mestdagh; Jo Vandesompele
Journal:  JCI Insight       Date:  2018-12-06

2.  Risk stratification and therapeutics of neuroblastoma: the challenges remain.

Authors:  Hong Mei; Zhen-Yu Lin; Qiang-Song Tong
Journal:  World J Pediatr       Date:  2016-01-19       Impact factor: 2.764

3.  Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.

Authors:  Qi Zhao; Mahiuddin Ahmed; Hong-fen Guo; Irene Y Cheung; Nai-Kong V Cheung
Journal:  J Biol Chem       Date:  2015-04-07       Impact factor: 5.157

4.  High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas.

Authors:  Pramila Ramani; Rachel Nash; Emile Sowa-Avugrah; Chris Rogers
Journal:  J Neurooncol       Date:  2015-08-29       Impact factor: 4.130

5.  Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma.

Authors:  Annalisa Pezzolo; Angela Rita Sementa; Margherita Lerone; Martina Morini; Marzia Ognibene; Raffaella Defferrari; Katia Mazzocco; Massimo Conte; Anna Rita Gigliotti; Alberto Garaventa; Vito Pistoia; Luigi Varesio
Journal:  Cancer Biol Ther       Date:  2017-04-12       Impact factor: 4.742

6.  Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis.

Authors:  Josephine H HaDuong; Laurence Blavier; Sanjeev K Baniwal; Baruch Frenkel; Jemily Malvar; Vasu Punj; Richard Sposto; Yves A DeClerck
Journal:  Int J Cancer       Date:  2015-02-21       Impact factor: 7.396

7.  ALK positively regulates MYCN activity through repression of HBP1 expression.

Authors:  Shana Claeys; Geertrui Denecker; Kaat Durinck; Bieke Decaesteker; Liselot M Mus; Siebe Loontiens; Suzanne Vanhauwaert; Kristina Althoff; Caroline Wigerup; Daniel Bexell; Emmy Dolman; Kai-Oliver Henrich; Lea Wehrmann; Ellen M Westerhout; Jean-Baptiste Demoulin; Candy Kumps; Tom Van Maerken; Genevieve Laureys; Christophe Van Neste; Bram De Wilde; Olivier De Wever; Frank Westermann; Rogier Versteeg; Jan J Molenaar; Sven Påhlman; Johannes H Schulte; Katleen De Preter; Frank Speleman
Journal:  Oncogene       Date:  2018-12-11       Impact factor: 9.867

8.  Structural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody.

Authors:  Irena Horwacik; Przemyslaw Golik; Przemyslaw Grudnik; Michal Kolinski; Michal Zdzalik; Hanna Rokita; Grzegorz Dubin
Journal:  Mol Cell Proteomics       Date:  2015-07-15       Impact factor: 5.911

9.  N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma.

Authors:  Michael B Armstrong; Rajen J Mody; D Christian Ellis; Adam B Hill; David A Erichsen; Daniel S Wechsler
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

10.  MYCN Silencing by RNAi Induces Neurogenesis and Suppresses Proliferation in Models of Neuroblastoma with Resistance to Retinoic Acid.

Authors:  Ruhina Maeshima; Dale Moulding; Andrew W Stoker; Stephen L Hart
Journal:  Nucleic Acid Ther       Date:  2020-04-02       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.